Josep Comin Colet

Summary

Publications

  1. doi request reprint A Cost-effectiveness Analysis of Ferric Carboxymaltose in Patients With Iron Deficiency and Chronic Heart Failure in Spain
    Josep Comín-Colet
    Programa de Insuficiencia Cardiaca, Servicio de Cardiologia, Hospital del Mar, Barcelona, Spain Grupo de Investigación Biomédica en Enfermedades del Corazón, Programa de Investigación en Procesos Inflamatorios y Cardiovasculares, Instituto de Investigaciones Médicas IMIM, Hospital del Mar, Barcelona, Spain Departamento de Medicina, Universidad Autonoma de Barcelona, Barcelona, Spain Electronic address
    Rev Esp Cardiol (Engl Ed) 68:846-51. 2015
  2. pmc The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study
    Josep Comín-Colet
    Heart Failure Programme, Department of Cardiology, and Research in Inflammatory and Cardiovascular Disorders Programme, IMIM Hospital del Mar Parc de Salut Mar, Passeig Maritim, 25 29, 08003, Barcelona, Spain
    Eur Heart J 34:30-8. 2013
  3. ncbi request reprint [Advances in heart failure]
    Josep Comin Colet
    Programa de Insuficiencia Cardiaca, Servicio de Cardiologia, Hospital del Mar IMAS, Barcelona, Espana
    Rev Esp Cardiol 62:92-100. 2009
  4. doi request reprint A pilot evaluation of the long-term effect of combined therapy with intravenous iron sucrose and erythropoietin in elderly patients with advanced chronic heart failure and cardio-renal anemia syndrome: influence on neurohormonal activation and clinical ou
    Josep Comín-Colet
    Department of Cardiology, Heart Failure Program, Hospital del Mar IMAS, Barcelona, Spain
    J Card Fail 15:727-35. 2009

Collaborators

Detail Information

Publications4

  1. doi request reprint A Cost-effectiveness Analysis of Ferric Carboxymaltose in Patients With Iron Deficiency and Chronic Heart Failure in Spain
    Josep Comín-Colet
    Programa de Insuficiencia Cardiaca, Servicio de Cardiologia, Hospital del Mar, Barcelona, Spain Grupo de Investigación Biomédica en Enfermedades del Corazón, Programa de Investigación en Procesos Inflamatorios y Cardiovasculares, Instituto de Investigaciones Médicas IMIM, Hospital del Mar, Barcelona, Spain Departamento de Medicina, Universidad Autonoma de Barcelona, Barcelona, Spain Electronic address
    Rev Esp Cardiol (Engl Ed) 68:846-51. 2015
    ..The aim of this study was to assess the cost-effectiveness of ferric carboxymaltose treatment vs no treatment in these patients...
  2. pmc The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study
    Josep Comín-Colet
    Heart Failure Programme, Department of Cardiology, and Research in Inflammatory and Cardiovascular Disorders Programme, IMIM Hospital del Mar Parc de Salut Mar, Passeig Maritim, 25 29, 08003, Barcelona, Spain
    Eur Heart J 34:30-8. 2013
    ..This detailed subanalysis of the previously published FAIR-HF study evaluated baseline HRQoL in iron-deficient patients with CHF and the effect of intravenous ferric carboxymaltose (FCM) on HRQoL...
  3. ncbi request reprint [Advances in heart failure]
    Josep Comin Colet
    Programa de Insuficiencia Cardiaca, Servicio de Cardiologia, Hospital del Mar IMAS, Barcelona, Espana
    Rev Esp Cardiol 62:92-100. 2009
    ..Novel approaches to the surgical management of patients with heart failure, including new contributions in the field of the circulatory support, are also highlighted in this update...
  4. doi request reprint A pilot evaluation of the long-term effect of combined therapy with intravenous iron sucrose and erythropoietin in elderly patients with advanced chronic heart failure and cardio-renal anemia syndrome: influence on neurohormonal activation and clinical ou
    Josep Comín-Colet
    Department of Cardiology, Heart Failure Program, Hospital del Mar IMAS, Barcelona, Spain
    J Card Fail 15:727-35. 2009
    ..The prognosis in elderly patients with advanced chronic heart failure (CHF) and cardio-renal anemia syndrome (CRAS) is ominous, and treatment alternatives in this subset of patients are scarce...